Safety, pharmacokinetic and pharmacodynamic profiles of single ascending doses of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 248)

Trial Profile

Safety, pharmacokinetic and pharmacodynamic profiles of single ascending doses of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 248)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 27 Feb 2017 New trial record
    • 20 Feb 2017 Results of three phase II studies published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top